Analysts think SONN stock price could increase by 1689%
Jun 14, 2024, 6:29 AM
-46.20%
What does SONN do
Sonnet BioTherapeutics Holdings, Inc., a clinical-stage biotech company headquartered in Princeton, New Jersey, focuses on oncology with its proprietary FHAB technology to enhance drug delivery to cancer tumors. The company, which went IPO in 2005, develops notable assets like SON-1010 for solid tumors and SON-080 for neuropathic conditions.
5 analysts think SONN stock price will increase by 1689.47%. The current median analyst target is $30.60 compared to a current stock price of $1.71. The lowest analysts target is $7.07 and the highest analyst target is $46.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
